Fairvalue-Calculator Fairvalue-Calculator
EN DE

Tongling Jieya Biologic Technology Co (301108) Fair Value & Analysis

Consumer Defensive · CN · Market cap 2.8B CNY

Price¥25.14
Fair Value¥12.79
Upside-49.1%
Quality95/100
Evidence: Medium Range ¥12.77 – ¥15.77

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Tongling Jieya Biologic Technology Co (301108) currently trades at ¥25.14, while our model-based Fair Value estimate is ¥12.79 — implying the stock looks roughly 49.1% overvalued today. We read business quality at 95/100 (high quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Tongling Jieya Biologic Technology Co., Ltd. engages in the research and development, production, and sales of wet wipe products in China. It offers baby, adult functional, antibacterial and disinfection, household clearing, medical care, pet cleaning wipes, wet toilet papers. The company also provides beauty care products, such as emollient water, Lotion, Cream, Essence, Membranes, clean, Body Series, Children's series, and Hair series, as well as facial masks and cleaning products. Tongling Jieya Biologic Technology Co., Ltd. was founded in 1999 and is based in Tongling, China.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is Tongling Jieya Biologic Technology Co (301108) undervalued?
As of Jun 24, 2026, our model estimates a fair value of ¥12.79 versus a price of ¥25.14 — about −49% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 301108?
Our 21-model fair value for Tongling Jieya Biologic Technology Co is ¥12.79 (as of Jun 24, 2026), built from audited fundamentals. The current price is ¥25.14.
What is the quality score of 301108?
Tongling Jieya Biologic Technology Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.